These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19901109)

  • 1. Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib.
    Védy D; Muehlematter D; Rausch T; Stalder M; Jotterand M; Spertini O
    J Clin Oncol; 2010 Jan; 28(3):e33-5. PubMed ID: 19901109
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
    Schalk E; Neum S; Kranz S; Scheinpflug K; Mohren M
    Leuk Res; 2009 Mar; 33(3):e6-7. PubMed ID: 18466968
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
    Dvorak P; Hruba M; Subrt I
    Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
    [No Abstract]   [Full Text] [Related]  

  • 4. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
    Kondo T; Tasaka T; Sano F; Matsuda K; Kubo Y; Matsuhashi Y; Nakanishi H; Sadahira Y; Wada H; Sugihara T; Tohyama K
    Leuk Res; 2009 Sep; 33(9):e137-8. PubMed ID: 19371951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.
    Nanri T; Matsuno N; Kawakita T; Mitsuya H; Asou N
    Leukemia; 2005 Sep; 19(9):1673-5. PubMed ID: 16049512
    [No Abstract]   [Full Text] [Related]  

  • 8. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
    Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM; Bendit I; Epelman S
    Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
    Merante S; Orlandi E; Bernasconi P; Calatroni S; Boni M; Lazzarino M
    Haematologica; 2005 Jul; 90(7):979-81. PubMed ID: 15996937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
    Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
    [No Abstract]   [Full Text] [Related]  

  • 15. C-kit-positive acute myelogenous leukemia effectively treated with imatinib: a case report and review of the literature.
    Ichikawa K; Aritaka N; Sekiguchi Y; Sugimoto KJ; Imai H; Komatsu N; Noguchi M
    Geriatr Gerontol Int; 2012 Oct; 12(4):762-4. PubMed ID: 22998385
    [No Abstract]   [Full Text] [Related]  

  • 16. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
    Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review.
    Xie Z; Zhang F; Song E; Ge W; Zhu F; Hu J
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):e44-8. PubMed ID: 17428693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
    Mohamed AN; Pemberton P; Zonder J; Schiffer CA
    Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.